# OnCo record paper-intrigue-ripretinib-vs-sunitinib-jco-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-intrigue-ripretinib-vs-sunitinib-jco-2022" ;
  schema:name "INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib"@en ;
  schema:description "Ripretinib was not better than sunitinib as second-line treatment for gastrointestinal stromal tumour overall, but it was better tolerated and worked better in tumours with KIT exon 11 plus exon 17/18 secondary mutations, while sunitinib was better for exon 13/14 mutations."@en ;
  schema:url <https://onco.cc/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.22.00294>, <https://pubmed.ncbi.nlm.nih.gov/35947817/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.22.00294> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Bauer S, Jones RL, Blay JY, et al." ;
  onco:cancers <https://onco.cc/cancers/gist-imatinib-resistant/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/ripretinib/>, <https://onco.cc/drugs/sunitinib/> ;
  onco:journals <https://onco.cc/journals/jco/> .